Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions, after a weekly, subcutaneous shot from Pfizer was cleared for NHS use. The ...

Haemophilia B Marstacimab (Hympavzi) is available on the NHS as an option for preventing bleeding episodes caused by haemophilia B in people 12 years and over who: weigh at least 35 kg have below 1% ...

The Haemophilia Society said it expects NICE's new guidance to be confirmed in March with Altuvoct becoming available in July.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress ...

CSL Behring's gene therapy Hemgenix for haemophilia B has been backed for reimbursement in England and Denmark.

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year. Marstacimab will be ...

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 ...

The first patient in the UK has been treated by the NHS with CSL Behring’s haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec). The patient from the North East of England was treated at ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for ...

On World Haemophilia Day, Jens Oltrogge reviews the progress made in treating this rare disorder, which causes those with the disease to bleed because of a lack of sufficient clotting factor ...

The International Society on Thrombosis and Haemostasis (ISTH) prepares to welcome nearly 5,000 attendees from the global thrombosis and hemostasis community to the ISTH 2025 Congress in ...

New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated with no safety ...